On April 28, 2026 Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the "Company"), reported the publication of its annual results and annual financial report for the 2025 financial year, [available on its website under the "Financial Information" section], and outlines the key pillars of its strategic roadmap.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"2025 was a year of profound transformation for Valerio Therapeutics. We clarified our strategic direction, strengthened our scientific foundations and continued to validate our technology platforms. The Company’s strategy is built around three pillars: internal programs, partnerships/licensing, and the creation of subsidiaries. Our first subsidiary, InVimmune, represents an important milestone and opens up highly attractive opportunities in indications with significant unmet medical needs. At the same time, we continue to strengthen our teams and reinforce our expertise in order to accelerate the development of our technology platforms and pipeline. We believe that our talents, together with the network of experts surrounding Valerio, will enable the Company to achieve its objectives," said Julien Miara, Chief Executive Officer of the Company.
Strategic refocusing
Following the structural transformation of its operating model initiated in 2025, aimed at refocusing its activities in order to concentrate its resources on preclinical opportunities with strong value-creation and partnership potential, the Company now focuses its efforts on the development of its proprietary V-Body and integrated chemistry platforms, which form the foundation of its next phase of growth.
This strategic refocusing has translated into concrete progress: Valerio Therapeutics has continued to strengthen the scientific and technological foundations of its platform portfolio, while generating encouraging preclinical results supporting the potential of its targeted delivery approach. The Company is thereby building a differentiated position in the field of extrahepatic oligonucleotide delivery and continuing to advance internal programs in therapeutic areas with high unmet medical needs.
As part of the structuring and scalability of its model, Valerio Therapeutics reached an important milestone with the creation of InVimmune, the Company’s first subsidiary, focused on in vivo cell therapy. This initiative marks a new step in Valerio’s ambition to organize its future growth around targeted therapeutic opportunities and to maximize the value of its platforms, both through internal development and partnership options.
Strengthening of the financial position
At the same time, the Company continued to strengthen its financial profile in 2025. Through a combination of restructuring measures, increased cost discipline and the continued support of its reference shareholders, Valerio Therapeutics improved its financial flexibility and consolidated the foundations needed to execute its strategy.
In June 2025, the Company finalized an agreement allowing it to extend the maturity of its bank debt and to reduce or reschedule its payables with its main suppliers.
The Company’s financial visibility is also supported by revenues from existing partnerships, as well as ongoing discussions aimed at entering into new value-creating agreements.
Partnerships and operational structure
Partnerships are a central pillar of Valerio Therapeutics’ model. During the financial year, the Company entered into several collaboration and research agreements, validating the attractiveness of its technology platforms and the relevance of its scientific approach.
Building on this momentum, Valerio anticipates sustained growth in its partnership activities in 2026, with the aim of generating new revenues, increasing its visibility and supporting the deployment of its development ambitions.
Recent operational progress also illustrates this new phase of development. The Company’s relocation to its new offices and laboratories within the PSCC in Villejuif strengthens its operational activities and its anchoring within a leading scientific ecosystem, and provides an additional lever to accelerate its research work, develop new collaborations and support the scale-up of its activities.
Financial results
The 2025 financial year was marked by revenue of €2.6 million, compared with €1.8 million for the 2024 financial year. This revenue mainly derived from royalties received under the license agreement, as well as partnership agreements entered into by the Company.
The Group recorded a significant decrease in operating expenses, which amounted to €4.8 million, compared with €18.3 million in the previous financial year.
The Group’s cash and cash equivalents amounted to €1.0 million as of December 31, 2025, compared with €1.2 million as of December 31, 2024.
(Press release, Valerio Therapeutics, APR 28, 2026, View Source [SID1234669253])